Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study

Research output: Contribution to journalArticlepeer-review

Abstract

Rotavirus vaccine protects against severe rotavirus-related gastroenteritis. Its effectiveness is substantially lower in low- and middle-income countries (LMICs) compared to high-income settings, partly due to interference from maternally derived rotavirus-specific immunoglobulin G (IgG) resulting from high rotavirus burden. These antibodies wane over time, reducing their capacity to inhibit vaccine-induced immune responses, including immunoglobulin A (IgA). We aimed to estimate the optimal window for administering an additional rotavirus vaccine dose, beyond the routine doses given at 6 and 10 weeks of age, to maximise immunogenicity in an LMIC, high-disease-burdened setting.

Original languageEnglish
Article numbere1004734
JournalPLoS Medicine
Volume22
Issue number9
DOIs
Publication statusPublished - 12 Sept 2025

Themes

  • Maternal, Neonatal, Sexual and Reproductive Health
  • Emerging and Re-Emerging Diseases

Fingerprint

Dive into the research topics of 'Maternal-infant rotavirus-specific antibody kinetics to inform timing of vaccine boosting in Malawi: An observational study'. Together they form a unique fingerprint.

Cite this